



BOD/SJS

PLEASE STAMP TO ACKNOWLEDGE RECEIPT OF THE FOLLOWING:

3

In Re Application of: Bernward SCHÖLKENS et al.

Application No.: 09/645,556

Group Art Unit: 1617

Filed: August 25, 2000

Examiner: M. Bahar

For: PHARMACEUTICAL FORMULATIONS AND USE THEREOF IN THE PREVENTION OF
STROKE, DIABETES AND/OR CONGESTIVE HEART FAILURE

1. Supplemental Information Disclosure Statement Under 37 C.F.R. §1.97(b) (2 pages);
2. Form PTO-1449 (1 page), including two documents

Dated: June 24, 2004

Docket No.: 02481.1702

SJS/V. Simmons - Mail Drop 848



(Due Date: N/D/D)

6/25/04
SJS



PATENT
Customer No. 22,852
Attorney Docket No. 02481.1702

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Bernward SCHÖLKENS et al.) Group Art Unit: 1617
)
Application No.: 09/645,556) Examiner: Jennifer Kim
)
Filed: August 25, 2000)
)
For: PHARMACEUTICAL)
FORMULATIONS AND USE)
THEREOF IN THE PREVENTION)
OF STROKE, DIABETES AND/OR)
CONGESTIVE HEART FAILURE)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97(c)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Supplemental Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final action, Quayle action, or a Notice of Allowance. Each document listed in this Supplemental Information Disclosure Statement was first cited in a communication from the European Patent Office in a counterpart foreign application, and this Supplemental Information Disclosure Statement is being filed within three months of the mailing date of that communication.

Copies of the listed documents are attached.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: June 24, 2004

By: 

Steven J. Scott
Reg. No. 43,911

**INFORMATION DISCLOSURE CITATION**

OMB No. 0651-0011

Atty. Docket No.	02481.1702	Appln. No.	09/645,556
Applicant	Bernward SCHÖLKENS et al.		
Filing Date	August 25, 2000	Group:	1617

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
EP 0 482 498 A2	29 Apr. 1992	Europe			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Willa A. Hsueh, MD, "In diabetes, treat hidden heart disease," Cleveland Clinic Journal of Medicine, vol. 67, no. 11, pages 807-813, November 2000

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce



PATENT
Customer No. 22,852
Attorney Docket No. 02481.1702

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Bernward SCHÖLKENS et al.) Group Art Unit: 1617
)
Application No.: 09/645,556) Examiner: J. Kim
)
Filed: August 25, 2000)
)
For: PHARMACEUTICAL) Confirmation No.: 3278
FORMULATIONS AND USE)
THEREOF IN THE PREVENTION)
OF STROKE, DIABETES AND/OR)
CONGESTIVE HEART FAILURE)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97(d)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(d), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed after a Final and is accompanied by a fee of \$180.00 as specified under § 1.17(p) and a certification as specified under § 1.97(e). Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

Each document listed in this Information Disclosure Statement was first cited in a communication from the Russian Patent Office in a counterpart foreign application, and this Information Disclosure Statement is being filed within three months of the mailing date of that communication.

Copies of the listed documents, English translations of the non-English documents, and a copy of the Official Action with an English language translation are enclosed.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: October 6, 2004

By: _____



Steven J. Scott
Reg. No. 43,911



OMB No. 0651-0011

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	024817702	Appln. No.	09/645,556
Applicant	Bernard SCHÖLKENS et al.		
Filing Date	August 25, 2000	Group:	1617

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	V.I. Metelitsa, "Handbook on Clinical Pharmacology of Cardiovascular Medicaments," Medpraktika, 1996, pp. 619 and 272, with English language translation of portion of text
	M.I. Balabolkin, "Endocrinology," Universum Publishing, pp. 390-391, 1998, with English language translation of portion of text
	P. Trenkwalder, "Effects of candesartan cilexetil on glucose homeostasis," Basic Res Cardiol, 93:Suppl. 2, pp. 140-144, 1998

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce